Iroko's meloxicam meets in Phase III OA pain trial

Iroko Pharmaceuticals LLC (Philadelphia, Pa.) said once-daily 5 and 10 mg doses of SoluMatrix meloxicam each met the primary endpoint of reducing mean pain scores from baseline to week 12 vs. placebo ...